{"id":155124,"date":"2026-11-19T16:30:21","date_gmt":"2026-11-19T07:30:21","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4918-20261119-01_wp_product_announcement\/"},"modified":"2026-11-19T16:30:21","modified_gmt":"2026-11-19T07:30:21","slug":"4918-20261119-01_wp_product_announcement","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/","title":{"rendered":"Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026"},"content":{"rendered":"<p>A patent grant was received at the national phase for the new anti-cancer substance &#8220;24-position di-substituted cholesterol glycoside.&#8221; The co-applicant is Kogakuin University. The Company will consider licensing agreements and applications in the pharmaceutical field, suggesting potential license fee revenues within the patent term. There are many uncertainties, and the impact on financial results is TBD.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4918","jir_company_name":"Ivy Cosmetics Corporation","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4918-20261119-01.pdf","jir_short_summary":"A patent grant was received at the national phase for the new anti-cancer substance \"24-position di-substituted cholesterol glycoside.\" The co-applicant is Kogakuin University. The Company will consider licensing agreements and applications in the pharmaceutical field, suggesting potential license fee revenues within the patent term. There are many uncertainties, and the impact on financial results is TBD.","jir_summary":"### Overview and Business Significance\nThe receipt today of a patent grant following the PCT national phase entry for the anti-cancer substance \"24-position di-substituted cholesterol glycoside\" means that the joint development results between Kogakuin University and Ivy Cosmetics Corporation will be legally protected. Following registration of the patent right, the Company plans to promote practical social use through licensing to pharmaceutical manufacturers. The patent is a composition-of-matter patent, enabling the right holder to exclusively manufacture and sell the compound. There is a possibility of long-term license revenue.\n\n### Impact and Future Actions\nThe invention has high potential for industrial application, and licensing agreements assuming applications in the pharmaceutical field are expected. The patent term is valid until September 17, 2045, with a possible extension mechanism of up to 5 years for pharmaceuticals. The direct immediate impact on financial results is TBD, and the Company intends to seek milestone-based contracts. Progress in related development and the status of license agreements will be disclosed going forward.","jir_financial_highlights":"Person Responsible for Patent Acquisition and Maintenance Procedures: Unknown (Unknown)","jir_category":"","jir_hashtags":"#IvyCosmetics, #NewAntiCancerCompound, #PatentGrant","jir_key_figures":"Patent term: Until September 17, 2045\nFuture potential for license fees: uncertain, not specified\nJoint application: 50:50 rights ratio with Kogakuin University","jir_meta_title":"Ivy Cosmetics Corporation \u2014 Patent Grant Received for New Anti-Cancer Compound | November 2026","jir_meta_description":"Ivy Cosmetics Corporation announces receipt of a patent grant following national phase entry for the jointly filed new anti-cancer compound \"24-position di-substituted cholesterol glycoside.\" The Company aims to pursue social application through licensing, with potential pharmaceutical applications noted.","jir_og_title":"Ivy Cosmetics Corporation \u2014 Patent Grant Received for New Anti-Cancer Compound | November 2026","jir_og_description":"Ivy Cosmetics Corporation received a patent grant for its jointly filed new anti-cancer compound. Licensing agreements in the pharmaceutical field are being considered, which could become a future revenue source. Many uncertainties remain at this stage.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":61099,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-155124","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026 - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/\",\"name\":\"Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026 - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-19T07:30:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026 - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/","url":"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/","name":"Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026 - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-19T07:30:21+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4918\/ir\/4918-20261119-01_wp_product_announcement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Notification Regarding Grant of Patent Following National Phase Entry of International (PCT) Application for Anti-Cancer Substance (New Compound) on November 19, 2026"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"61099","title":"IVY COSMETICS CORP","ticker":"4918"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/155124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=155124"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/155124\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=155124"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=155124"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=155124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}